ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Subscribe To Our Newsletter & Stay Updated
